Immune checkpoint molecules, also known as cosignaling molecules, are pivotal cell-
surface molecules that control immune cell responses by either promoting (costimulatory …

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%,
emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be …

Background/Aims Hepatocellular carcinoma (HCC), accounting for 75-85% of primary liver
cancer cases, is the third leading cause of cancer-related death worldwide. The purpose of …

CD96 is a promising candidate for immunotherapy. However, its role and importance in
glioma remains unknown. We thus aimed to genetically and clinically characterize CD96 …

The crosstalk between NK cells and their surrounding environment is enabled through
activating and inhibitory receptors, which tightly control NK cell activity. The co-inhibitory …

Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular
carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality …

Background Although checkpoint-based immunotherapy has shown exciting results in the
treatment of tumors, around 70% of patients have experienced unresponsiveness. PVRIG is …

Natural killer (NK) cells represent a subset of CD3-CD7+ CD56+/dim lymphocytes with
cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall …

Systematic interrogation of tumor-infiltrating immune cells (TIICs) is key to the prediction of
clinical outcome and development of immunotherapies. However, little is known about the …

The discovery of CTLA-4 and PD-1 checkpoints has prompted scientific researchers and the
pharmaceutical industry to develop and conduct extensive research on tumor-specific …